Insider Selling: GeneDx (NASDAQ:WGS) COO Sells $510,857.70 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) COO Bryan Dechairo sold 5,961 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $85.70, for a total value of $510,857.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Bryan Dechairo also recently made the following trade(s):

• On Monday, February 2nd, Bryan Dechairo sold 3,413 shares of GeneDx stock. The stock was sold at an average price of $99.53, for a total transaction of $339,695.89.

GeneDx Price Performance

NASDAQ WGS opened at $84.29 on Monday. The company has a current ratio of 2.71, a quick ratio of 2.59 and a debt-to-equity ratio of 0.18. The company has a 50-day moving average price of $126.14 and a two-hundred day moving average price of $125.22. The stock has a market cap of $2.44 billion, a price-to-earnings ratio of 936.56 and a beta of 2.01. GeneDx Holdings Corp. has a 52 week low of $55.17 and a 52 week high of $170.87.

Institutional Trading of GeneDx

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers raised its position in GeneDx by 42.7% in the second quarter. Rhumbline Advisers now owns 27,610 shares of the company’s stock worth $2,549,000 after purchasing an additional 8,258 shares in the last quarter. Legal & General Group Plc grew its position in GeneDx by 55.9% during the 2nd quarter. Legal & General Group Plc now owns 22,271 shares of the company’s stock worth $2,056,000 after acquiring an additional 7,987 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of GeneDx during the second quarter worth $589,000. Legal Advantage Investments Inc. grew its holdings in GeneDx by 19.8% during the 2nd quarter. Legal Advantage Investments Inc. now owns 60,600 shares of the company’s stock worth $5,594,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. acquired a new position in shares of GeneDx during the third quarter worth approximately $31,488,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

WGS has been the topic of several research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of GeneDx in a research report on Wednesday, January 21st. Canaccord Genuity Group lifted their price target on GeneDx from $160.00 to $170.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Wall Street Zen downgraded shares of GeneDx from a “buy” rating to a “hold” rating in a research report on Sunday. Guggenheim restated a “buy” rating and issued a $170.00 target price (up previously from $115.00) on shares of GeneDx in a research note on Wednesday, October 29th. Finally, Wells Fargo & Company set a $155.00 target price on shares of GeneDx and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, GeneDx currently has a consensus rating of “Moderate Buy” and a consensus target price of $138.13.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.